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Endoplasmic reticulum stressBreast cancer is the second most common cancer with a high incidence rate worldwide. One of the promising
therapeutic approaches on breast cancer is to use the drugs that target the estrogen receptor (ER). In the present
investigation, marmorin, a type I ribosome inactivating protein from the mushroom Hypsizigus marmoreus,
inhibited the survival of breast cancer in vitro and in vivo. It evinced more potent cytotoxicity toward estrogen
receptor (ER)-positive MCF7 breast cancer cells than ER-negative MDA-MB-231 cells. Further study disclosed
that marmorin undermined the expression level of estrogen receptor α (ERα) and signiﬁcantly inhibited the
proliferation of MCF7 cells induced by 17β-estradiol. Knockdown of ERα in MCF7 cells signiﬁcantly attenuated
the inhibitory effect of marmorin on proliferation, suggesting that the ERα-mediated pathway was implicated
in the suppressive action of marmorin on ER-positive breast cancer cells. Moreover, marmorin induced
time-dependent apoptosis in bothMCF7 andMDA-MB-231 cells. It brought about G2/M-phase arrest, mitochon-
drial membrane potential depolarization and caspase-9 activation in MCF7 cells, and to a lesser extent in
MDA-MB-231 cells. Marmorin triggered the death receptor apoptotic pathway (e.g. caspase-8 activation) and
endoplasmic reticulum stress (ERS, as evidenced by phosphorylation of PERK and IRE1α, cleavage of
caspase-12, and up-regulation of CHOP expression) in both MCF7 and MDA-MB-231 cells. In summary,
marmorin exhibited inhibitory effect on breast cancer partially via diminution of ERα and apoptotic pathways
mediated bymitochondrial, death receptor and ERS. The results advocate that marmorin is a potential candidate
for breast cancer therapy.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Breast cancer is the second most common cancer with a high
incidence rate worldwide [1]. More than 70% of breast cancer tissue
exhibited an elevated level of expression of estrogen receptor α
(ERα) compared with normal breast tissue, suggesting that ERα
plays a pivotal role in breast carcinogenesis [2,3]. ERα is a steroid
hormone receptor localized in the nucleus where it exerts its transcrip-
tional effect by interacting with 17β-estradiol (E2) and subsequently
binding to speciﬁc estrogen response elements in the promoter of target2, 17β-estradiol; ER, Estrogen
eceptor β; ERS, Endoplasmic
tein; IRE1α, Inositol-requiring
ndoplasmic reticulum kinase;
estrogen receptor modulator;
m, Mitochondrial membrane
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rights reserved.gene [4]. In addition, ERα can trigger transduction signaling pathways
through directly or indirectly interactingwith G-coupled proteins [4–6].
Accumulating evidence suggest that ERα mediates E2-dependent
G1–S phase transition by transcriptional up-regulation of helix-turn
protein Id1 [7] or Bcl-2-homology domain (BH3)-only protein
Noxa [8] 222which both counteract cell cycle checkpoints. Furthermore,
ERα-positive tumors manifest an overexpression of the anti-apoptotic
protein Bcl-2 [9] that prevents cells from undergoing mitochondrial-
dependent apoptosis. Therefore, the progression of ERα-positive cells
in benign breast lesions and tumors may escape from tumorigenesis
barrier that involves DNA replication stress leading to an activation of
the DNA damage checkpoint, cell cycle arrest and apoptosis [10,11].
The presence of ERα in breast cancer at the time of diagnosis is an indi-
cation for endocrine therapy [6] andmany therapeutic strategies thereby
focus on the drugs that target the estrogen receptor (ER). This kind
of drugs, which are categorized into two groups including selective
estrogen receptor modulators (SERM, such as tamoxifen) and selective
estrogen receptor down-regulator (SERD, such as fulvestrant), are highly
effective in breast cancer treatment, but their utility is restricted by
endocrine resistance [12]. Consequently, development of drugs that
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turns out to be a promising approach for breast cancer therapy.
Ribosome inactivating proteins (RIPs), which exhibit enzymatic
activity that brings about the cleavage of a speciﬁc adenine base
from ribosomal RNA, were ﬁrst isolated and characterized from the
seeds of the castor oil plant Ricinus communis [13]. RIPs were subse-
quently puriﬁed from more plants [14], bacteria [15], and fungi [16].
RIPs are classiﬁed into 3 types: (i) type I with a single polypeptide
chain displaying a molecular mass close to 30 kDa, (ii) type II with a
RIP chain and a lectin chain that facilitates internalization of the RIP
chain, and (iii) maize RIP, ﬁrst synthesized as an inactive precursor,
and considered as an atypical type I RIP/a type III RIP [16]. Recently,
small RIPs with a molecular mass of 20 kDa [17,18] or 10 kDa [19]
have also been identiﬁed from mushrooms.
It has been reported that type II RIPs, as well as free or conjugated
type I RIPs, induced cell apoptosis in vitro and in vivo [20,21]. Some
investigations have delineated the mechanism and pathways of
RIP-induced apoptosis. Ricin caused cell cycle arrest in Hela cells at
G2/M phase [22] and induced unfolded protein response in HCT116
and MDA-MB-231 cells [23]. Abrin induced apoptosis in Jurkat cells
via the mitochondrial pathway, independent of caspase-8 and hence
death receptors [21]. Shih et al. [24] observed that abrin-induced
apoptosis was independent of N-glycosidase activity, but attributed
to reduction of anti-oxidant activity of mitochondrial protein anti-
oxidant protein-1, with a consequent rise in reactive oxygen species
and cytochrome c release into the cytosol. Saporin induced apoptosis
through a mitochondrial cascade independent of translation inhibi-
tion [25]. Xiong et al. [26] demonstrated that bitter melon RIP
induced apoptosis in prostate cancer cells by inhibiting Wnt signal-
ing activity and histone deacetylase-1 activity. Viscumin evoked
apoptosis via a caspase-dependent pathway, with the expression
level of the anti-apoptotic protein Mcl-1 was down-regulated [27].
Trichosanthin has been demonstrated to induce a nitric oxide
(NO)-mediated apoptosis and also by generating reactive oxygen
species (ROS) [28]. Immunotoxins containing saporin and bouganin
can inhibit cell protein synthesis, induce apoptosis, and block clonogenic
growth of target cells, although with different kinetics. Thus there is a
diversity of mechanisms of cell killing [29]. It seems that the pathway
depends on the type of tumor cell and the type of RIP.
We have isolated a 9,567-Da RIP marmorin with a novel N-
terminal sequence from fresh fruiting bodies of the common edible
mushroom Hypsizigus marmoreus in a previous study [19]. Biological
characterization showed that marmorin displayed higher inhibitory
potency toward breast cancer MCF7 cells, liver cancer HepG2 cells
and HIV-1 reverse transcriptase compared with plant RIPs from
family Cucurbitaceae [19]. Since marmorin manifests a small molecu-
lar mass and a distinctive N-terminal sequence compared with other
RIPs, we were interested in ascertaining the mechanism of its inhibi-
tion of breast cancer cells. In this study, puriﬁed marmorin was found
to exert its anti-tumor activity on breast cancer cells in vitro
and in vivo. Interestingly, marmorin evinced more potent cytotox-
icity toward ER-positive MCF7 breast cancer cells than ER-
negative MDA-MB-231 cells. Both death receptor apoptotic path-
way (e.g. caspase-8 activation) and endoplasmic reticulum stress
(e.g. phosphorylation of PERK and IRE1α, cleavage of caspase-12,
and up-regulation of CHOP expression) were involved in marmorin-
induced apoptosis in MCF7 and MDA-MB-231 cells. The underlying
mechanism of the differential sensitivity of the two types of breast cancer
cells to marmorin was contributed by (a) diminution of the expression
level of ERα in ER-positive MCF7 cells, but deﬁciency of ERα in
ER-negative MDA-MB-231 cells, (b) induction of G2/M-phase arrest in
MCF7 cells, and also in MDA-MB-231 cells but to a much smaller extent,
(c) activation of a mitochondrial-mediated apoptotic pathway in MCF7
cells (as witnessed in reduction of GRP75 expression, cleavage of
caspase-9 and mitochondrial membrane potential depolarization), and
not in MDA-MB-231 cells (as evidenced by negligible mitochondrialmembrane potential depolarization and lack of an effect on GRP75
expression and cleavage of caspase-9).
2. Materials and methods
2.1. Materials
Human breast cancer MCF7 and MDA-MB-231 cells were obtained
from American Type Culture Collection. Human umbilical vein
endothelial cells (HUVEC) were generously provided by Prof. Y. Huang
(School of Biomedical Sciences, The Chinese University of Hong Kong).
Transformed human nasopharyngeal epithelial NP 69 cells were
generously provided by Prof. S.W. Tsao (Department of Anatomy, The
University of Hong Kong). Primary antibodies against PERK (#3192),
IRE1α (#3294), CHOP (#2895), β-actin (#4970), caspase-12 (#2202),
caspase-9 (#9502) and caspase-3 (#9662), and secondary antibodies
for HRP-linked anti-mouse IgG (#7076) and anti-rabbit IgG (#7074)
were purchased from Cell Signaling Technology (Danvers, MA, USA).
Primary antibodies for ERα (sc-542), GRP75 (sc-31652) and p53
(sc-6243) were acquired from Santa Cruz Biotechnology (CA, USA).
Primary antibody for ERβ (Q92731) was obtained from Millipore
(Darmstadt, Germany). Primary antibody for capase-8 (551243) was
purchased from BD Pharmingen (CA, USA).
2.2. Preparation of marmorin
Marmorin was isolated as described in a previous study [19]. Brieﬂy,
fresh fruiting bodies of Hypsizigus marmoreus (2 kg) were extracted by
homogenizing in 2 l of 0.15 M NaCl at 4 °C. The supernatant obtained
after centrifugation was subsequently subjected to ion exchange
chromatography on a (DEAE)–cellulose column (5 cm diameter×10 cm
length, Sigma, USA) in 10mM Tris–HCl buffer (pH 7), an Afﬁ-gel blue gel
column (2.5 cm×15 cm, Bio-Rad, UK) in 20 mM NH4HCO3 buffer
(pH 9.4) and a gel-ﬁltration Superdex 75 HR 10/30 FPLC column
(GE Healthcare) in 20 mM NH4HCO3 buffer (pH 9.4).
2.3. Cell culture and cell viability assessment
Cells were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM,
Gibco, Grand Island, USA) containing 10% fetal bovine serum (Hyclone,
Gramlington, UK), 100 U/ml penicillin and 100 μg/ml streptomycin
(Millipore, Darmstadt, Germany). After growing to 70–80% conﬂuence,
cells (5×103–6×103)were trypsinized and seeded into a 96-well plate.
After incubation for 24 h, the cells were treatedwith increasing concen-
trations (0–20 μM) ofmarmorin for 48 h, and cell viability was assessed
by the MTT assay as previously described [30].
2.4. Annexin V and propidium iodide (PI) dual staining
The percentage of cells undergoing apoptosis was determined
by ﬂow cytometry (FACSCanto I, BD, New Jersey, USA) using dual
staining with Annexin V–FITC (BD Phamingen, CA, USA) and
propidium iodide (PI, Sigma) as previously described [31]. Brieﬂy,
after seeding on a 12-well culture plate for 24 h, MCF7 and MDA-
MB-231 cells (105) were treated with 5 and 15 μM marmorin for
different durations (0, 12, 24, 36, and 48 h), respectively. Then the
cells were trypsinized, centrifuged and washed thrice with phosphate
buffered saline (PBS). The cell pellets were resuspended in binding
buffer (0.01 M HEPES, pH 7.4, containing 140 mM NaCl and 25 mM
CaCl2) for subsequent Annexin V/PI staining and ﬂow cytometry
analysis.
2.5. siRNA assay
Double-stranded siRNA against ERα (ESR1-homo-1014) and non-
speciﬁc siRNA (negative control) were purchased from Shanghai
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UGU UGA AAC ATT-3′; ESR1-homo-1014 reverse: 5′-UGU UUC AAC
AUU CUC CCU CTT-3′. Negative control forward: 5′-UUC UCC GAA
CGU GUC ACG UTT-3′; negative control reverse: 5′-ACG UGA CAC
GUU CGG AGA-3′. ESR1-homo-1014 or negative control siRNA (ﬁnal
concentration: 50 nmol/l) were transfected into MCF7 cells by using
Lipofectamine reagent (GIBCOBRL, MD, USA) for 36 h according
to the manufacturer's instructions. Then the transfected cells were
used for cell viability and apoptosis assays. The efﬁciency of knockdown
of ERα was monitored by western blotting analysis of protein
expression.
2.6. Cell cycle analysis and measurement of mitochondrial membrane
potential (ΔΨm) depolarization
MCF7 and MDA-MB-231 cells (105) were treated for different
durations with 5 and 15 μM marmorin, respectively. For cell cycle
analysis, cells were trypsinized and stained with PI (50 μg/ml PI in
PBS, containing 0.05% Triton X-100 and 1 mg/ml RNase A) at 4 °C
overnight with avoidance of exposure to light. Then the cell cycle
was analyzed using ﬂow cytometry. For ΔΨm detection, cells were
stainedwith 2.5 mg/ml JC-1,which can accumulate in themitochondria
as aggregates that emit red ﬂuorescence. When ΔΨm depolarization
occurs, JC-1 is localized in monomeric form in the cytosol and emits
green ﬂuorescence.
2.7. Western blot analysis
After cells had been treated with marmorin for different durations,
cell lysates were extracted by using RIPA lysis buffer (50 mM Tris-HCl
buffer, pH 8.0, containing 150 mM NaCl, 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS) containing 1 mM phenylmethylsulfonyl
ﬂuoride (PMSF) and protease cocktail inhibitor. Then cell lysates
were subjected to Western blot analysis using antibody mentioned
in Materials, as previously described [32]. The results were quantiﬁed
by plotting the density of the band using Quantity One Version 4.6.2.
2.8. Tumor xenografted assay
The animal assayswere approved by Animal Experimentation Ethics
Committee of The Chinese University of Hong Kong. Five-week-old
nude mice (16–20 g) were kept in isolated pathogen-free ventilation
chambers. Cell suspension was obtained by trypsinization of conﬂuent
breast cancer cells. The carcinoma was established by subcutaneously
injecting 107 MCF7 or MDA-MB-2311 cells into nude mice. MCF7 cells
require estrogen for xenografted tumor formation; thus 100 μl agonist
agent (2 mg 17-β estradiol dissolved in 1 ml olive oil) was subcutane-
ously injected into the nude mice every 5 days since the day before
tumor cells injection. Tumor volume (V) was measured according to
the following formula: V=L×W2/2, where L is the mid-axis length
and W is the mid-axis width. When tumors reached a mean size
of 100–200 3, xenograft-bearing mice were divided into groups with 6
animals per group. Marmorin (2 mg/kg) dissolved in PBS was adminis-
tered daily by intraperitoneal injection for 19 days. Tumor volume was
measured every 3 days using a digital caliper. When the experiment
ended, all animals were sacriﬁced by cervical dislocation. Their tumors
were excised and weighed.
2.9. TUNEL staining and immunoblotting analysis of tumor specimens
The tumor specimens collected from xenograft-bearing mice were
divided into two portions: one for histological analysis by TUNEL
staining assay, and the other for immunoblotting. For TUNEL staining,
tumor specimens were ﬁxed in 4% formalin and embedded in parafﬁn
wax. Sections (4-μm-thick) were cut and subjected to immunostaining
with In Situ Cell Death Detection Kit (Roche, Germany) as permanufacturer's instructions, and then viewed under a ﬂuorescence
microscope. For immunoblotting, tumor specimens were homogenized
in RIPA lysis buffer at 4 °C. Then cell lysates were extracted by centrifu-
gation (14,000 g) for 30 min at 4 °C and subsequent immunoblotting
analysis was performed as previously described [32].
2.10. Statistics analysis
Results were collected from 3 independent experiments conducted
in triplicate, and data are expressed as mean±SD. The histograms
were drawn using Origin Version 6.0. Student’s t test and two-way
ANOVA were used for between-group comparisons. A P valueb0.05
was considered as statistically signiﬁcant.
3. Results
3.1. Cytotoxicity of marmorin on breast cancer cells partially mediated by
reduction of ERα expression
MTT assay was used to investigate the in vitro antitumor activity of
marmorin. Breast cancer MCF7 and MDA-MB-231 cells, transformed
human nasopharyngeal epithelial NP 69 cells and human umbilical
vein endothelial cells (HUVEC) were exposed to increasing concen-
trations (0–20 μM) of marmorin for 48 h, respectively. As shown
in Fig. 1A, marmorin exerted more potent cytotoxicity on estrogen
receptor (ER)-positive MCF7 breast cancer cells (IC50=5 μM) than
ER-negative MDA-MB-231 cells (IC50=15 μM). In contrast, there
was no inhibitory effect toward NP 69 cells (Fig. 1A). Interestingly,
marmorin inhibited, in a dose-dependent manner, proliferation of
HUVEC which is critical to angiogenesis (Fig. 1A). Further investigation
disclosed that marmorin reduced the expression level of estrogen
receptor α (ERα) but not that of estrogen receptor β (ERβ) (Fig. 1B;
Fig. S1A). The proliferation of MCF7 cells induced by 10 nM 17β-
estradiol (E2), which can up-regulate the expression level of ERα
(Fig. 1C; Fig. S1B), was signiﬁcantly suppressed by 0.5 or 5 μM
marmorin (Fig. 1C). Moreover, knockdown of ERα in MCF7 cells signif-
icantly attenuated the inhibitory effect of marmorin on proliferation
(Fig. 1D). These results suggested that the ERα-mediated signaling
pathway was involved in the inhibitory action of marmorin on ER-
positive breast cancer cells.
3.2. Marmorin induced apoptosis in MCF7 and MDA-MB-231 cells
To characterize the type of cell death induced by marmorin,
Annexin V/PI dual staining was used to evaluate the apoptotic cells.
MCF7 and MDA-MB-231 cells were treated with 5 and 15 μM
marmorin respectively for different durations (0, 12, 24, 36, and
48 h). As shown in Fig. 1E, marmorin induced time-dependent
apoptosis in both MCF7 and MDA-MB-231 cells, with the effect on
MCF7 cells being more pronounced. Furthermore, the percentage of
apoptotic cells induced by marmorin decreased when ERα was
knocked down by siRNA in MCF7 cells (Fig. 1F). These results
unveiled that marmorin-induced apoptosis was partially dependent
on the reduction of ERα in ER-positive MCF7 cells.
3.3. Exposure to marmorin induced G2/M phase arrest and DNA breakage
in MCF7 cells, and to a lesser extent in MDA-MB-231 cells
ERα has been demonstrated to indirectly promote G1/S progression
through counteracting cell cycle checkpoint in breast cancer cells [7,8].
To further investigate the role of ERα-mediated signaling in the
cytotoxicity of marmorin, cell cycle analysis of MCF7 and MDA-MB-
231 cells was conducted after treatment with 5 and 15 μM marmorin,
respectively, for different durations (0, 6, 12, 24, 36, and 48 h).
As shown in Fig. 2A, marmorin induced a drastic time-dependent G2/M
phase arrest with a decline in the proportion of G1/S-phase cells and a
Fig. 1. Cytotoxicity of marmorin to breast cancer cells was partially mediated by reduction of ERα expression. (A) Breast cancer MCF7 and MDA-MB-231 cells, transformed human
nasopharyngeal epithelial NP 69 cells and human umbilical vein endothelial cells (HUVEC) were respectively exposed to increasing concentrations (0–20 μM) of marmorin for 48 h.
MTT assay was used to detect cell viability. *Pb0.05, **Pb0.01 and ***Pb0.001, when compared with control. (B) Western blot analysis of estrogen receptor α (ERα) and estrogen
receptor β (ERβ) expression after MCF7 cells had been treated with 5 μM marmorin for different durations as indicated, respectively. β-Actin served as an intrinsic control.
*Pb0.05 and **Pb0.01, when compared with control. #Pb0.05, when compared with E2 treatment alone. (C) MCF7 cells were treated with 10 nM 17β-estradiol (E2), 0.5 or 5 μM
marmorin alone or co-treated with 10 nM E2 and 0.5 or 5 μM marmorin for 48 h, respectively. Then the cells were subjected to MTT assay (upper panel) or western blot analysis
(lower panel). (D) The double-stranded siRNA against ERα (siRNA ERα) and non-speciﬁc siRNA (siRNA NC) were transfected into MCF7 cells for 36 h. Then the cells were used
for western analysis (upper panel) or cell viability assessment after treatment with 5 μMmarmorin for 48 h (lower panel) as indicated. **Pb0.01 and ***Pb0.001, when compared
with control. #Pb0.05, when compared with siRNA NC cells treated with 5 μM marmorin for 48 h. (E) Marmorin induced time-dependent apoptosis in breast cancer cells in vitro.
MCF7 and MDA-MB-231 cells were treated with 5 and 15 μM marmorin for different durations as indicated, respectively. Flow cytometry analysis of marmorin-induced apoptosis
using Annexin V/PI dual staining. (F) The double-stranded siRNA against ERα (siRNA ERα) and non-speciﬁc siRNA (siRNA NC) were transfected into MCF7 cells for 36 h. Then the
cells were treated with 5 μMmarmorin for 36 h and subsequent apoptosis analysis using Annexin V/PI dual staining.
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MCF7 cells. An analogous change, albeit to a lesser extent, was detected
in MDA-MB-231 cells (Fig. 2B). Western blotting analysis revealed
that the expression level of p53, which plays a pivotal role in
cell cycle checkpoint, was up-regulated when MCF7 cells were
exposed to marmorin (Fig. 2C; Fig. S1D). However, marmorin did
not enhance p53 expression level in MDA-MB-231 cells (Fig. 2C;
Fig. S1D). These results conﬁrmed that marmorin exhibited cytotoxic-
ity via the induction of p53-dependent G2/M arrest in ER-positivebreast cancer MCF7 cells, and also in ER-negative MDA-MB-231 cells,
albeit to a lesser extent.
3.4. Marmorin induced differentiated mitochondrial collapse and death
receptor apoptotic pathway in MCF7 and MDA-MB-231 cells
In view of RIP-induced apoptosis referred to two classical pathways
mediated respectively by mitochondria and death receptor [21], the
factors contributing to these two pathways were investigated after
Fig. 2. Exposure of MCF7 cells to marmorin induced G2/M phase arrest and DNA breakage, and to a lesser extent of MDA-MB-231 cells. (A) MCF7 cells and (B) MDA-MB-231 cells
were treated with 5 and 15 μMmarmorin for different durations as indicated. Flow cytometry analysis of cell cycle using PI staining. The percentage of cells in G0/G1, S, and G2/M
phases of the cell cycle is presented in the upper panel and sub-G0 phase cells which represents an indicator of DNA damage is shown in lower panel. (C) Western blot analysis of
p53 expression. MCF7 and MDA-MB-231 cells were respectively treated with 5 and 15 μM marmorin for different durations as indicated. β-Actin served as an intrinsic control.
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12, 24, 36, and 48 h) with 5 and 15 μM marmorin, respectively.
Western blot analysis unveiled that cleavage of caspase-8 accounting
for the death receptor pathway was found in both MCF7 and MDA-
MB-231 cells (Fig. 3A; Fig. S1E and F). Caspase-3, which is deﬁcient in
MCF7 cells, downstream of caspase-8, was also activated in MDA-
MB-231 cells (Fig. 3A; Fig. S1F). Regarding the mitochondrial pathway,
marmorin suppressed the expression level of mitochondrial chaperone
GRP75 (mtHsp70) and cleavage of caspase-9 (Fig. 3A; Fig. S1E) inMCF7
cells, but not in MDA-MB-231 cells. Furthermore, ﬂow cytometry
analysis of mitochondrial membrane potential (ΔΨm) disclosed that
marmorin treatment produced a marked time-dependent ΔΨm
depolarization in MCF7 cells, and also in MDA-MB-231 cells, though to
a lesser extent (Fig. 3B). Overall, marmorin triggered bothmitochondrial
and death receptor apoptotic pathways in MCF7 cells, while it preferen-
tially activated the death receptor-mediated pathway in MDA-MB-231
cells.3.5. Marmorin induced endoplasmic reticulum stress (ERS) in both MCF7
and MDA-MB-231 cells
In addition to the pathways of death receptor- and mitochondria-
mediated apoptosis, prolonged activation of the unfolded protein
response (UPR) in the endoplasmic reticulum stress (ERS) would lead
to programmed cell death [33]. Three known pro-apoptotic pathways
in response to ERS are mediated by PERK, IRE1 and caspase-12, respec-
tively [34,35], which converge to a b-ZIP transcription factor CHOP that
induces expression of genes favoring apoptosis [35] or subsequently
activates caspase-3 [36].
The factors responsible for ERS hereby were considered after treat-
ment of MCF7 and MDA-MB-231 cells for different durations with 5
and 15 μMmarmorin, respectively (0, 6, 12, 24, 36, and 48 h). Western
blot analysis revealed that marmorin induced phosphorylation of
IRE1α, cleavage of caspase-12, and up-regulation of the expression
level of CHOP in both MCF7 and MDA-MB-231 cells (Fig. 4; Fig. S1G
Fig. 3.Marmorin induced differentiated mitochondrial collapse and death receptor apoptotic pathway in MCF7 and MDA-MB-231 cells. MCF7 and MDA-MB-231 cells were treated
with 5 and 15 μM marmorin for different durations as indicated, respectively. (A) Western blot analysis of the factors contributed to mitochondrial and death receptor pathways.
Primary antibodies against GRP75, capsase-8, caspase-9 and caspase-3 were used. β-Actin served as an intrinsic control. (B) Flow cytometry analysis of mitochondrial membrane
potential depolarization using JC-1 staining. Percentage of cells undergoing mitochondrial membrane potential depolarization was recorded.
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cells, but not in MDA-MB-231 cells (Fig. 4; Fig. S1G and H). The results
indicated that the apoptotic effect of marmorin on MCF7 and MDA-
MB-231 cells was partially attributed to ERS.
3.6. Marmorin suppressed the growth of xenografted tumor bearing
MCF7 or MDA-MB-231 cells
In order to determine the in vivo anti-tumor activity of marmorin,
MCF7 and MDA-MB-231 cells (107) were injected subcutaneously
into nude mice to facilitate development of tumor xenografted,
respectively. When tumors attained a mean size of 100–200 mm3,Fig. 4. Marmorin induced endoplasmic reticulum stress (ERS) in both MCF7 and MDA-MB-
different durations as indicated, respectively. The factors responsible for ERS, such as PERK
served as an intrinsic control.the mice received intraperitoneal injections of marmorin (2 mg/kg/day).
In contrast to the vehicle control, marmorin treatment for 13 days led
to a decline of tumor volume in the xenografted tumor (Fig. 5A and D).
At the termination of the experiment, all nude mice were sacriﬁced by
cervical dislocation, and their tumors were excised (Fig. 5C and F). As
revealed in Fig. 5B and E, marmorin signiﬁcantly suppressed the tumor
weight compared with the vehicle control. For further investigation,
MDA-MB-231 xenografted tumor specimens were used for histological
and immunoblot analysis. As shown in Fig. 6A, marmorin greatly
increased the amount of TUNEL-positive cells compared with the vehicle
control, signifying that marmorin stimulated DNA breakage in the MDA-
MB-231 xenografted tumor. Furthermore, immunoblotting analysis231 cells. MCF7 and MDA-MB-231 cells were treated with 5 and 15 μM marmorin for
, IRE1α, caspase-12 and CHOP, were investigated using western blot analysis. β-Actin
Fig. 5. Marmorin halted the growth of xenografted tumor involving MCF7 or MDA-MB-231 cells. (A, D) MCF7 cells or MDA-MB-231 cells (107) were injected subcutaneously into
the nude mice. Marmorin (2 mg/kg/day) and vehicle control were administered intraperitoneally into xenografted mice, respectively. After treatment for 19 days, mice were
sacriﬁced by cervical dislocation, and their tumor specimens were excised (C, F) and weighed (B, E). *Pb0.05, when compared with control.
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IRE1α and cleavage of caspase-12, but not PERK (Fig. 6B; Fig. S1I).
Intriguingly, marmorin induced cleavage of caspase-9 in xenografted
tumor involving MDA-MB-231 cells (Fig. 6B), which was contra-
dictory to the in vitro outcome (Fig. 3A). These results furnishedevidence that marmorin halted the growth of MDA-MB-231
xenografted tumor through cleavage of DNA and ERS. Moreover,
marmorin caused the diminution of ERα expression in MCF7
xenografted tumor (Fig. S2), which was in line with the ﬁnding
in vitro (Fig. 1B).
Fig. 6. Marmorin induced apoptosis in MDA-MB-231 xenografted tumor by eliciting DNA damage and ERS. (A) MDA-MB-231 xenografted tumor specimens were subjected to
immunostaining with In Situ Cell Death Detection Kit, and then viewed under ﬂuorescent microscope. DNase I recombinant served as a positive control of a reagent causing
DNA breakage. (B) Western blot analysis of cell lysates extracted from MDA-MB-231 xenografted tumor specimens using primary antibodies of PERK, IRE1α, caspase-12 and
caspase-9. β-Actin served as an intrinsic control.
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It is well documented that RIPs are capable of inducing apoptosis
in cancer cells by provoking several cellular stresses [21]. It is demon-
strated herein that the type I RIP marmorin suppresses the in vitro
and in vivo growth of breast tumors with a mechanism that entails
reduction of ERα expression, endoplasmic reticulum stress (ERS), and
mitochondrial- and death receptor-mediated apoptotic pathways. It is
reported for the ﬁrst time here that an RIP could down-regulate the
expression level of ERα in ER-positive breast cancer cells. The results
imply that marmorin is a candidate for treatment of breast cancers
and provide a new insight into cancer therapy using RIPs.
The major ﬁnding of this study is that marmorin inhibits the
expression level of ERα and the proliferation induced by E2 in ER-
positive MCF-7 cells. This implies that an ER-mediated signaling path-
way is required for the manifestation of the effects of marmorin. ERα
is a well-known promoter of both the onset and malignant progression
of breast cancer through ligand-dependent transcription or ligand-
independent activation [6]. Drugs that target ER are classiﬁed into
two groups: selective estrogen receptor modulators (SERM, such as
tamoxifen) [37] and selective estrogen receptor down-regulator
(SERD, such as fulvestrant) [38]. Here, we present evidence that a
type I RIP marmorin can speciﬁcally down-regulate the expression
level of ERα but not that of ERβ, although it is not known whether
marmorin modulates ERα by a direct or indirect mode. Furthermore,
the observation that marmorin brings about a prominent G2/M phase
cell cycle arrest in MCF7 cells, but not inMDA-MB-231 cells, is probably
associated with the down-regulation of the expression of ERα which
induces carcinogenesis predominantly bymeans of cell cyclemanipula-
tion [7,8]. As expected,marmorinproduced inMCF7 cells, after treatment
for 6 h, a pronounced increase of cells remaining in G2/M-phase (Fig. 2A)
concurrent with the marked decrement of ERα expression (Fig. 1B). p53
response and DNA damage, in turn, participate in marmorin-induced
apoptosis of MCF7 cells (Fig. 1E).
Another outcome that contributed to the attenuation of ERα
expression is that marmorin dramatically activates mitochondrial-
mediated apoptotic pathway in MCF7 cells, but to a less remarkable
extent inMDA-MB-231 cells. Generally, themitochondrial-mediated ap-
optotic pathway is associatedwith factors anchored on themitochondria.The insertion of these pro-apoptotic proteins on mitochondria alters
the mitochondrial membrane permeability, ensuing in the release of
cytochrome c that can activate caspase-9 and downstream caspase-3,
eventually leading to cell apoptosis [39]. Consistent with this paradigm,
a considerable number of MCF7 cells undergoing ΔΨm depolarization
and caspase-9 activation (Fig. 3) were observed after treatment with
marmorin for 12 h, and the continuing stressﬁnally brought about exten-
sive apoptosis at 36 h (Fig. 1E). In contrast, even though a large number
of MDA-MB-231 cells underwent apoptosis after treatment with
marmorin for 24 h (Fig. 1E), the cells demonstrated only slight ΔΨm
depolarization and there was no caspase-9 activation (Fig. 3). It has
been reported that ERα inﬂuenced the survival of breast cancer cells
through regulation of Bcl-2/BclXL [7–9]. Therefore, abrogation of the
stimulatory effect of ERα on overexpression of Bcl-2 that prevents the
insertion of pro-apoptotic proteins on mitochondria facilitates the initia-
tion of mitochondrial apoptotic pathway in MCF7 cells. Collectively,
the above phenomena may account for the discrepancy between the
sensitivity of MCF7 and MDA-MB-231 cells to marmorin.
Apart from modulation of ERα expression, results of this study
indicate that marmorin induces death receptor and ERS apoptotic
pathway in both MCF7 and MDA-MB-231 cells. Caspase-8 activation
is a conspicuous feature of the death receptor-mediated apoptotic
pathway [39]. Although the death receptor-mediated apoptotic path-
way was engaged in both MCF7 and MDA-MB-231 cells after admin-
istration of marmorin (e.g. cleavage of capsase-8, Fig. 4A), caspase-8
stimulated different downstream signaling events in these two
cell lines due to deﬁciency of caspase-3 in MCF7 cells. Caspase-8
ampliﬁed the mitochondrial apoptotic loop through cleavage of the
BH3 protein Bid that creates holes in themitochondria leading tomito-
chondrial collapse [39], whichwas expected inmarmorin-treatedMCF7
cells (e.g.ΔΨmdepolarization and caspase-9 activation, Fig. 3). Alterna-
tively, caspase-8 directly cleaved caspase-3 culminating in cell death
[39], which was discernible at 12 h in MDA-MB-231 cells following
exposure to marmorin (Fig. 3A). Interestingly, the effect of marmorin
on cleavage of caspase-3 was sustained until 12 h in MDA-MB-231
cells, hinting that this action contributed to the early cytotoxicity of
marmorin. To further prolong the impact, marmorin needs to launch
another apoptotic pathway, such as ERS. CHOP, which is regulated by
three known pathways [34,35], is a key mediator of ERS-induced
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promoter of TRB3 gene [41]. As anticipated, we found that marmorin
markedly heightened the level of expression of CHOP later, at 24, 36
and 48 h, in both MDA-MB-231 and MCF7 cells. In MCF7 cells, long-
term anti-ER treatment engenders drug resistance regarding prolifera-
tive AKT/PI3K signaling [42]. Hence, marmorin, as a SERD, seems to be
competent for circumventing this resistance to endocrine therapy via
up-regulation of CHOP expression.
In a nude mouse model involving MDA-MB-231 cells, we discover
that marmorin restrains the growth of breast cancer in vivo. Devoid of
induction of inﬂammation, apoptosis is the favorable mode of killing
cancer cells in vivo [39]. In conformity with in vitro results, marmorin
induced DNA damage and ERS that elicited apoptosis in mice bearing
MDA-MB-231 xenografted tumor (Fig. 6). Also, marmorin down-
regulated the expression level of ERα (Fig. S2) in MCF7 xenografted
tumor. In addition, marmorin hindered angiogenesis through lower-
ing the viability of HUVEC (Fig. 1A) in vitro. These observations
suggest that marmorin also starves tumors to death through
diminishing the amount of blood vessels in vivo. Our data also
unveiled that marmorin exerted no cytotoxicity on normal NP69
cells (Fig. 1A), as well as WRL-68 embryonic liver cells [19] in vitro.
At the conclusion of the in vivo experiment, the tumor-bearing mice
were dissected. No abnormalities were noted in the viscera and
organs (data not shown), signifying that the dosage of marmorin
(2 mg/kg/day) is safe for usage in mice. Surprisingly, inconsistent
with the upshot in MDA-MB-231 cells, marmorin provoked cleavage
of caspase-9 in tumor bearing nude mice. Zhang et al. [43] showed
that the apoptotic rate in maspin-expressing tumor cells was increased
upon treatment with serum starvation, and that maspin-mediated
apoptosis was partially offset by an inhibitor of caspase-9. This discrep-
ancy was probably attributed to the inhibitory effect of marmorin on
angiogenesis, which caused the xenografted tumor to go into starvation
which increased the likelihood of the MDA-MB-231 xenografted tumor
undergoing caspase-9 mediated apoptotic pathway.
In summary, marmorin exerts cytotoxicity on breast cancers both
in vitro and in vivo. Marmorin initiates the mitochondrial apoptotic
pathway by modulation of ERα expression in ER-positive MCF7
cells. Furthermore, marmorin targets the death receptor and ERS
apoptotic pathways in both ER-positive and -negative breast cancers.
It seems that triggering a variety of apoptotic pathways enhanced the
anti-tumor effect of marmorin. Moreover, the anti-proliferative activity
of marmorin on HUVEC cells implies an anti-angiogenic and hence
anti-metastatic potential. These observations indicate the potential
utility of marmorin for breast cancer therapy.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.12.013.References
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